Cefepime (Maxipime)

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Also Known As:

Maxipime; Axépim; BMY 28142; BMY-28142; Cefepim; Cefepime Hydrochloride; Quadrocef; BMY28142; Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-

Networked: 1100 relevant articles (139 outcomes, 214 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Nicolau, David P: 28 articles (07/2022 - 06/2004)
2.	Kuti, Joseph L: 13 articles (07/2022 - 07/2005)
3.	Scheetz, Marc H: 8 articles (01/2022 - 06/2015)
4.	Roberts, Jason A: 8 articles (12/2021 - 02/2007)
5.	Ko, Wen-Chien: 7 articles (10/2022 - 02/2013)
6.	Rybak, Michael J: 7 articles (06/2020 - 08/2002)
7.	Jones, Ronald N: 7 articles (10/2017 - 03/2002)
8.	Paterson, David L: 6 articles (11/2021 - 10/2005)
9.	Knechtle, Philipp: 6 articles (01/2021 - 01/2019)
10.	Tamma, Pranita D: 6 articles (04/2020 - 09/2013)

Related Diseases

1.	Infections 01/01/2000 - "The excellent activity against most Gram negative and Gram positive pathogens suggests that cefepime may be useful in the treatment of serious infections in the described patient population." 01/01/2011 - "High efficacy of Quadrocef preparation and possibility of its application as a first-line preparation for severe infections was proved." 01/01/1989 - "The high in vitro activity of cefepime was reflected in its in vivo efficacy against experimental infections in normal and immuno-suppressed mice. " 02/01/2008 - "The T>MIC values (8 h) of cefepime suggested that this agent is clinically effective in the treatment of various infections." 06/01/2000 - "The results of this study show that cefepime is a safe and effective agent in the treatment of adult patients with severe infection in Taiwan."
2.	Neoplasms (Cancer) 08/01/1997 - "Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. " 04/29/2021 - "This study was conducted at a cancer referral center, and study participants were receiving 2 g IV doses of cefepime every 8 h as 30-min infusions. " 11/01/2014 - "The purpose of this study was to compare the efficacy and safety of CZOP with cefepime (CFPM) empirical monotherapy in pediatric cancer patients with FN. " 08/01/1997 - "Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients." 06/01/2022 - "The objective of this study is to retrospectively evaluate the efficacy of cefepime 1 g every 6 h versus 2 g every 8 h in cancer patients with febrile neutropenia. "
3.	Pneumonia (Pneumonitis) 01/01/1999 - "Our data suggest that cefepime was safe and effective for treatment of severe pneumonia in hospitalized patients." 01/01/2018 - "In this article, we report a case of an 84-year-old Caucasian male who was diagnosed with Shewanella pneumonia treated with cefepime with minimal to no improvement in his symptoms. " 01/01/2012 - "Patient's pneumonia improved with treatment with cefepime. " 09/26/2023 - "aeruginosa pneumonia treated with cefepime versus other susceptible agents. " 01/01/2021 - "We report the first documented case of EP secondary to cefepime for the treatment of pneumonia. "
4.	Sepsis (Septicemia) 02/01/2009 - "The aims of this study were to compare the efficacy of cefepime IV at a dose of 1 g q8h (adjusted based on renal function) with those of other appropriate antimicrobials in the treatment of gramnegative pulmonary and bloodstream infections and to identify risk factors for treatment failure. " 11/01/2018 - "In conclusion, use of cefepime or TZP for management of AmpC bloodstream infections was associated with clinical and microbiological cure with infrequent selection for resistance." 12/14/2015 - "Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival." 09/01/2002 - "In the cefepime group, a patient with Salmonella paratyphi A septicemia was cured, which has not been previously reported. " 11/09/2023 - "The Impact of the Implementation of a Pharmacist-Driven Protocol of Second Dose Cefepime for Adult Patients With Sepsis in the Emergency Department at a Tertiary Care Academic Medical Center."
5.	Febrile Neutropenia 08/31/2023 - "Cefepime prophylaxis was associated with a significant reduction in BSIs, febrile neutropenia, and ICU admission among pediatric AML patients." 01/01/2017 - "The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis." 03/01/2021 - "Our study identified no differences in clinical outcomes with cefepime 1 g q6h compared to the traditional FDA-approved 2 g q8h regimen for the treatment of febrile neutropenia." 04/01/2018 - "Larger clinical trials are necessary to determine if EI cefepime imparts a clinical benefit in the treatment of febrile neutropenia." 04/01/2018 - "The aim of this study was to determine the feasibility and clinical impact of administering cefepime by EI as treatment of febrile neutropenia. "

Related Drugs and Biologics

1.	Ceftazidime (Fortum)
2.	Meropenem (Merrem)
3.	Ceftriaxone (Ceftriaxon)
4.	Tazobactam Drug Combination Piperacillin (Zosyn)
5.	Anti-Bacterial Agents (Antibiotics)
6.	Amikacin (A.M.K)
7.	Cephalosporins (Cephalosporin Antibiotics)
8.	Cefotaxime (Kendrick)
9.	Imipenem
10.	Cefepime (Maxipime)

Related Therapies and Procedures

1.	Therapeutics
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
3.	Continuous Renal Replacement Therapy
4.	Cholecystectomy
5.	Antibiotic Prophylaxis